Angela N Koehler

Title: Angela N Koehler: Innovator in Cancer Therapy and Diagnostics

Introduction

Angela N Koehler is a prominent inventor based in Belmont, MA (US). She has made significant contributions to the field of cancer therapy and diagnostics, holding a total of 7 patents. Her work focuses on innovative approaches to enhance the efficacy of lipid-based nanoparticle treatments.

Latest Patents

One of her latest patents is centered around the solute carrier family 46 member 3 (SLC46A3) as a marker for lipid-based nanoparticle cancer therapy and diagnostics. SLC46A3 has been identified as a lipid-based nanoparticle-specific biomarker predictive of nanoparticle-cancer cell affinity. The research indicates that SLC46A3 has a strong inverse association with lipid-based nanoparticle uptake across multiple nanoparticle formulations. Tissues with decreased expression levels of SLC46A3 exhibit greater uptake of lipid-based nanoparticles. This inverse relationship has therapeutic and diagnostic implications, including cancer therapy and diagnosis, and the identification of patients most likely to benefit from lipid-based nanotherapeutics for improved stratification in clinical trials. Another significant patent involves small molecule inhibitors of Interleukin-4, focusing on IL-4 and/or IL-13 inhibitors and their uses.

Career Highlights

Angela has worked with prestigious institutions such as the Massachusetts Institute of Technology and Dana-Farber Cancer Institute Inc. Her research has been pivotal in advancing the understanding of nanoparticle interactions with cancer cells.

Collaborations

Angela has collaborated with notable colleagues, including Eric Stefan and Francisco Caballero, contributing to her innovative research and development efforts.

Conclusion

Angela N Koehler's work exemplifies the intersection of innovation and healthcare, particularly in cancer treatment. Her patents and research continue to pave the way for advancements in therapeutic strategies and patient care.